Balchem's second quarter arrived with a quiet, almost mechanical, kind of strength: every one of the company's three reportable segments set a record for either sales or operating income or both, the consolidated top line of $284.0 million grew 11.2% year over year, and adjusted EBITDA of $77.9 million set a fresh quarterly high. Net earnings of $44.6 million rose 16.6% and GAAP diluted EPS of $1.39 (up from $1.17) cleared the prior-year quarter even after a step-up in the effective tax rate. Behind those numbers, two structural forces are doing real work: the European Commission's final anti-dumping duties of 90.0% to 115.9% on Chinese choline chloride imports - in effect since July 2025 and made definitive in December 2025 - have effectively closed a low-cost import channel into the European Union; and management used the cash flow to repurchase $29 million of stock in the quarter ($114 million trailing twelve months) while renegotiating the company's revolving credit facility up to $650 million (from $550 million) and extending it to July 2031. The print is the moment a specialty-ingredients company that has been grinding for years demonstrates that pricing power, mix, and a regulatory tailwind can move three segments in the same direction at the same time. The open question for the equity is whether Q3 and Q4 can keep all three engines running at a double-digit revenue pace, with management's most recent quarterly filing already flagging higher manufacturing input costs and tariff-related inflation as the offsets management is absorbing rather than passing through.